JP2021519089A5 - - Google Patents
Info
- Publication number
- JP2021519089A5 JP2021519089A5 JP2020551924A JP2020551924A JP2021519089A5 JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5 JP 2020551924 A JP2020551924 A JP 2020551924A JP 2020551924 A JP2020551924 A JP 2020551924A JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- protein complex
- complex according
- based chimeric
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024006808A JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649238P | 2018-03-28 | 2018-03-28 | |
| US201862649264P | 2018-03-28 | 2018-03-28 | |
| US201862649248P | 2018-03-28 | 2018-03-28 | |
| US62/649,264 | 2018-03-28 | ||
| US62/649,238 | 2018-03-28 | ||
| US62/649,248 | 2018-03-28 | ||
| PCT/US2019/024714 WO2019191519A1 (en) | 2018-03-28 | 2019-03-28 | Bi-functional proteins and construction thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Division JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519089A JP2021519089A (ja) | 2021-08-10 |
| JP2021519089A5 true JP2021519089A5 (enExample) | 2022-04-05 |
Family
ID=68060793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551924A Pending JP2021519089A (ja) | 2018-03-28 | 2019-03-28 | 二官能性タンパク質およびその作製 |
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210024631A1 (enExample) |
| EP (1) | EP3773674A4 (enExample) |
| JP (2) | JP2021519089A (enExample) |
| KR (1) | KR20210005872A (enExample) |
| CN (1) | CN112512551A (enExample) |
| AU (2) | AU2019243580A1 (enExample) |
| CA (1) | CA3095310A1 (enExample) |
| WO (1) | WO2019191519A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| KR102642385B1 (ko) * | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP4029877B1 (en) | 2017-08-03 | 2024-01-17 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| AU2018313810B2 (en) * | 2017-08-09 | 2025-05-15 | Orionis Biosciences BV | Clec9A binding agents and use thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| KR102877915B1 (ko) * | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| US12410225B2 (en) * | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| US20220177550A1 (en) * | 2019-03-28 | 2022-06-09 | Orionis Biosciences, Inc. | Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3) |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| WO2020212598A1 (en) | 2019-04-19 | 2020-10-22 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| WO2020250706A1 (ja) | 2019-06-12 | 2020-12-17 | ソニー株式会社 | 画像処理方法、および、メタデータのデータ構造 |
| US11636771B2 (en) | 2019-09-08 | 2023-04-25 | Deere & Company | Stackable housing containers and related systems |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| MX2022007035A (es) | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2021144415A1 (en) * | 2020-01-17 | 2021-07-22 | Universiteit Gent | Immunoglobulin single domain antibodies for delivery of mucosal vaccines |
| JP7512413B2 (ja) * | 2020-03-31 | 2024-07-08 | ビオテウス・インコーポレイテッド | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 |
| WO2021230460A1 (ko) * | 2020-05-14 | 2021-11-18 | 주식회사 제넥신 | Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도 |
| WO2022011005A1 (en) * | 2020-07-07 | 2022-01-13 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022089418A1 (zh) * | 2020-10-26 | 2022-05-05 | 信达生物制药(苏州)有限公司 | 重组截短FLT3配体与人抗体Fc的融合蛋白 |
| US20250186520A1 (en) * | 2020-10-26 | 2025-06-12 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| EP4262871A4 (en) * | 2020-12-18 | 2025-04-02 | Bioardis LLC | FAP-BINDING MOLECULES AND THEIR USES |
| EP4323392A4 (en) * | 2021-04-16 | 2025-03-19 | Orionis Biosciences, Inc. | IL-2-BASED CONSTRUCTS |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| CN118103407A (zh) * | 2021-08-12 | 2024-05-28 | 上海才致药成生物科技有限公司 | 一种双特异性重组蛋白及其用途 |
| US20240376198A1 (en) * | 2021-08-30 | 2024-11-14 | Inhibrx, Inc. | NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof |
| JP2024534838A (ja) * | 2021-08-30 | 2024-09-26 | インヒブルクス インコーポレイテッド | ＮＫｐ４６結合ポリペプチド及びその使用 |
| CN118317785A (zh) * | 2021-09-13 | 2024-07-09 | 根特大学 | 氨肽酶n特异性单克隆抗体及其用途 |
| WO2023056412A1 (en) * | 2021-09-30 | 2023-04-06 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| KR20250022000A (ko) * | 2022-04-07 | 2025-02-14 | 알레타 바이오쎄라퓨틱스, 인크. | 암 치료를 위한 조성물 및 방법 |
| WO2023201051A2 (en) * | 2022-04-15 | 2023-10-19 | Palleon Pharmaceuticals Inc. | Anti-inflammatory siglec-6 proteins and methods of making and using same |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| TW202525857A (zh) * | 2023-09-11 | 2025-07-01 | 大陸商上海才致藥成生物科技有限公司 | 長效副甲狀腺激素受體促效劑融合蛋白及其應用 |
| WO2025106775A1 (en) * | 2023-11-17 | 2025-05-22 | Orionis Biosciences, Inc. | Pd-l1-based chimeric protein formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327199D1 (de) * | 2002-04-26 | 2009-05-28 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening auf agonistische antikörper |
| EP2343081A1 (en) * | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| PT3513804T (pt) * | 2011-07-08 | 2022-06-02 | Bioverativ Therapeutics Inc | Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| PT2822575T (pt) * | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| US10544199B2 (en) * | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
| MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| WO2017077382A1 (en) * | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| WO2017137477A1 (en) * | 2016-02-09 | 2017-08-17 | Bracco Suisse Sa | A recombinant chimeric protein for selectins targeting |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2019
- 2019-03-28 KR KR1020207031008A patent/KR20210005872A/ko not_active Ceased
- 2019-03-28 US US17/042,512 patent/US20210024631A1/en active Pending
- 2019-03-28 CA CA3095310A patent/CA3095310A1/en active Pending
- 2019-03-28 EP EP19775640.6A patent/EP3773674A4/en active Pending
- 2019-03-28 WO PCT/US2019/024714 patent/WO2019191519A1/en not_active Ceased
- 2019-03-28 JP JP2020551924A patent/JP2021519089A/ja active Pending
- 2019-03-28 CN CN201980035145.6A patent/CN112512551A/zh active Pending
- 2019-03-28 AU AU2019243580A patent/AU2019243580A1/en not_active Abandoned
-
2024
- 2024-01-19 JP JP2024006808A patent/JP2024028543A/ja active Pending
-
2025
- 2025-05-28 AU AU2025203995A patent/AU2025203995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519089A5 (enExample) | ||
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Kontermann | Dual targeting strategies with bispecific antibodies | |
| EP3443006B1 (en) | Trispecific and/or trivalent binding proteins | |
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| JP2021118723A5 (enExample) | ||
| JP2022511135A (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JP7486810B2 (ja) | ＩｇＧ１ Ｆｃモノマー、及びその使用 | |
| JP2020036595A5 (enExample) | ||
| US20130295096A1 (en) | Degraded agonist antibody | |
| US12428493B2 (en) | Antibodies that bind PSMA and gamma-delta T cell receptors | |
| JP2010517538A5 (enExample) | ||
| CA2411374A1 (en) | Dual specificity antibodies and methods of making and using | |
| JP2023526282A5 (enExample) | ||
| JP2024521405A5 (enExample) | ||
| JP2025508882A5 (enExample) | ||
| CN116284396B (zh) | NKp46抗体及其用途 | |
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| Rossi et al. | Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α | |
| US20110165122A1 (en) | Method for targeted and sustained antiviral therapy | |
| JP2022550345A5 (enExample) | ||
| WO2001079494A1 (fr) | Anticorps agonistes | |
| JP2002544172A5 (enExample) | ||
| JP2025502205A5 (enExample) |